Skip to main content

Gibson Christopher's Form 4 filing

Recursion Pharmaceuticals, Inc. (RXRX) · filed Aug 5, 2022

Accession no.
0001209191-22-044668
Filed
Aug 5, 2022
Trade date
Aug 4, 2022
Filing delay
1 day
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 10 non-derivative transactions and 5 derivative transactions. Open-market sales total $373.1K. It was filed 1 day after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Gibson ChristopherCIK 0001856369Director, Officer (Chief Executive Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Aug 4, 2022Class A Common StockMOption exerciseAcquired+31,250$2.48+$77,500560,154Direct
Aug 4, 2022Class A Common StockSSaleDisposed−18,325$9.53F2−$174,637.25541,829Direct
Aug 4, 2022Class A Common StockCConversionAcquired+18,500$0.00$0560,329Direct
Aug 4, 2022Class A Common StockSSaleDisposed−18,500$9.45F4−$174,825541,829Direct
Aug 4, 2022Class A Common StockCConversionAcquired+500$0.00$0500Indirect
Aug 4, 2022Class A Common StockSSaleDisposed−500$9.44F6−$4,7200Indirect
Aug 4, 2022Class A Common StockCConversionAcquired+1,000$0.00$01,000Indirect
Aug 4, 2022Class A Common StockSSaleDisposed−1,000$9.45F8−$9,4500Indirect
Aug 4, 2022Class A Common StockCConversionAcquired+1,000$0.00$01,000Indirect
Aug 4, 2022Class A Common StockSSaleDisposed−1,000$9.45F10−$9,4500Indirect

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Aug 4, 2022Class A Common StockCConversionDisposed−18,500$0.00$06,751,334Direct
Aug 4, 2022Class A Common StockMOption exerciseDisposed−31,250$0.00$0918,886Direct
Aug 4, 2022Class A Common StockCConversionDisposed−500$0.00$0542,500Indirect
Aug 4, 2022Class A Common StockCConversionDisposed−1,000$0.00$0535,000Indirect
Aug 4, 2022Class A Common StockCConversionDisposed−1,000$0.00$0131,875Indirect

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

This transaction was executed in multiple trades at prices ranging from $9.51 to $9.64. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Referenced by the price of 1 transaction in Table I.

F4

This transaction was executed in multiple trades at prices ranging from $9.24 to $9.65. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Referenced by the price of 1 transaction in Table I.

F6

This transaction was executed in multiple trades at prices ranging from $9.26 to $9.62. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Referenced by the price of 1 transaction in Table I.

F8

This transaction was executed in multiple trades at prices ranging from $9.27 to $9.62. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Referenced by the price of 1 transaction in Table I.

F10

This transaction was executed in multiple trades at prices ranging from $9.24 to $9.62. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)